
May 7 (Reuters) - AstraZeneca PLC AZN.L:
ENHERTU® (FAM-TRASTUZUMAB DERUXTECAN-NXKI) FOLLOWED BY THP BEFORE SURGERY SHOWED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PATHOLOGIC COMPLETE RESPONSE IN HIGH-RISK HER2-POSITIVE EARLY-STAGE BREAST CANCER IN DESTINY-BREAST11